Mutations also occur in other genes such as SMAD4, BRIP1, CHEK2, MUTYH, HNF1A and XPC. Among all these gene mutations, KRAS has been considered as one of the ‘undruggable’ targets in cancer treatment [3]. Here, KRAS is linked to cancer.